European Medicines Agency, Amsterdam, the Netherlands, Netherlands
Disclosure information not submitted.
The nature of uncertainties on the benefit-risk balance of anticancer medicines at initial marketing authorisation in the European Union
Monday, August 26, 20242:30 PM – 2:45 PM CEST
